Luc M.
- Country
- France
- Department
- Internal medicine
Research Overview
- A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis
- Evaluation of Anifrolumab Efficacy and Safety in Systemic Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Prospective Multicenter Study on Early Discontinuation of Prednisolone in FDG-PET/CT Negative Patients with Idiopathic Retroperitoneal Fibrosis
Data & Insights
Has run more than one trial at 33 of 123 partner sites.
Specializations
Systemic Sclerosis Research
Focused investigation into treatments for systemic sclerosis, with particular emphasis on improving lung function and managing various manifestations of the condition.
- Pulmonary complications
- Disease progression markers
- Forced vital capacity assessment
Clinical evaluation of novel therapeutic approaches for systemic sclerosis management.
Cutaneous Disease Management
Specialized research in diffuse cutaneous systemic sclerosis, examining innovative therapeutic interventions and their effects on skin manifestations.
- Composite response indices
- Treatment efficacy measures
- Long-term disease outcomes
Investigation of targeted therapies for skin involvement in systemic sclerosis.
Retroperitoneal Disorders
Expert focus on idiopathic retroperitoneal fibrosis, investigating optimal treatment duration and monitoring strategies using advanced imaging techniques.
- Steroid therapy optimization
- FDG-PET/CT imaging
- Relapse prevention strategies
Development of evidence-based treatment protocols for fibrotic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.